title: Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
abstract: OBJECTIVE
  To assess the efficacy of moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori (H. pylori) eradication.
  
  
  METHODS
  Between January 2010 and December 2012, we screened individuals who were prescribed non-bismuth quadruple therapy for H. pylori eradication. Among them, a total of 98 patients who failed non-bismuth quadruple therapy received 1-wk or 2-wk moxifloxacin-containing triple therapy (400 mg moxifloxacin once daily, and 20 mg of rabeprazole and 1 g of amoxicillin twice daily). H. pylori status was evaluated using the (13)C-urea breath test 4 wk later, after treatment completion. The eradication rates were determined by intention-to-treat and per-protocol analyses.
  
  
  RESULTS
  In total, 60 and 38 patients received 1-wk and 2-wk moxifloxacin-containing triple therapy, respectively. The intention-to-treat and per-protocol eradication rates were 56.7% (95%CI: 45.0-70.0) and 59.6% (95%CI: 46.6-71.7) in the 1-wk group and 76.3% (95%CI: 63.2-89.5) and 80.6% (95%CI: 66.7-91.9) in the 2-wk group (P = 0.048 and 0.036, respectively). All groups had good compliance (95% vs 94.9%). Neither group showed serious adverse events, and the proportions of patients experiencing mild side effects were not significantly different (21.1% vs 13.9%). Clinical factors such as age, sex, alcohol and smoking habits, comorbidities, and presence of gastric or duodenal ulcer did not influence the eradication therapy efficacy. The efficacy of second-line eradication therapy did not differ significantly according to the first-line regimen.
  
  
  CONCLUSIONS
  Two-week moxifloxacin-containing triple therapy showed better efficacy than a 1-wk regimen after non-bismuth quadruple therapy failure.
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: Ji Hyun
authors.initials: JH
authors.lastname: Lim
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: Dong Ho
authors.initials: DH
authors.lastname: Lee
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: Seong Tae
authors.initials: ST
authors.lastname: Lee
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: Nayoung
authors.initials: N
authors.lastname: Kim
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Park
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: Cheol Min
authors.initials: CM
authors.lastname: Shin
authors.affiliation: Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
authors.forename: In Sung
authors.initials: IS
authors.lastname: Song
mesh_terms: D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D058491:Bacterial Load; D001944:Breath Tests; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000009:adverse effects; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D057194:Intention to Treat Analysis; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D064750:Rabeprazole / Q000008:administration & dosage; D019233:Retreatment; D012189:Retrospective Studies; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D000658:Amoxicillin; D000077266:Moxifloxacin
keywords: Eradication; Helicobacter pylori; Moxifloxacin-based triple; Non-bismuth quadruple; Second-line